Upcoming event

Tags

Abiraterone, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, ARCHES, Article of the Month, ASCO GU21, ASCO GU22, ASCO21, AUA21, BHC80, Biochemical recurrence, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, hormone-sensitive, HORRAD, HRQL, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, Prognosis, Prognostic model, Prostasomes, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PSA, PSA flare, PSA kinetics, PSA screening, PSMA PET/CT, PTEN, Quality of life, Radiation therapy, Radical prostatectomy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)

Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)

Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol

Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (prostate imaging reporting and data system/likert 3–5) and negative initial biopsy. A mini systematic review

European Urology, August 2022

African-specific molecular taxonomy of prostate cancer

Nature, August 2022

Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial

BJU International, August 2022

Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

, September 2022

Predicting the need for biopsy to detect clinically significant prostate cancer in patients with a magnetic resonance imaging–detected prostate imaging reporting and data system/Likert ≥3 Lesion: Development and multinational external validation of the imperial rapid access to prostate imaging and diagnosis risk score

European Urology, August 2022

Impact of left-digit age bias in the treatment of localized prostate cancer

Journal of Urology, July 2022

Satisfaction with clinician-led germline genetic counseling in patients with prostate cancer

Journal of Urology, August 2022

Local failure events in prostate cancer treated with radiotherapy: A pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)

European Urology, August 2022

Prostate-specific membrane antigen radioguided surgery to detect nodal metastases in primary prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Results of a planned interim analysis of a prospective phase 2 study

European Urology, July 2022

PreviousNext